News Release

2017.11.08

Noven Pharmaceuticals, Inc. press release :Noven files patent infringement lawsuit against Alvogen

2017.10.10

FY02/2018 Q2 Results Earnings Release Presentation

2017.09.25

Notification of the commencement of the Phase II clinical study of Investigational HP-5000 in the USA (an analgesic transdermal drug)

2017.08.31

Notification of submission of supplemental new drug application (NDA) for the addition of a new 0.5mg dose of the transdermal, long-action pain relief patch FENTOS® TAPE (development code:HFT-290)

2017.08.08

Announcement of Establishment of New Company

2017.07.18

Notification o f the commencement of the Phase III clinical study of HP-3150 in in Japan for “cancer pain” (an algesic transdermal drug containing NSAIDs)

2017.07.07

FY02/2018 Q1 Results Earnings Release Presentation

2017.05.26

Position and Policy Regarding Reduction in the Trading Unit of the Company’s Shares

2017.05.18

Salonpas Has Been Acknowledged as World’s No.1 OTC Topical Analgesics Patch Brand By Euromonitor International

2017.04.07

Announcement regarding Establishment of “the 6th Medium-term Management Policy” (Presentation Material)

2017.04.07

Announcement regarding Establishment of “the 6th Medium-term Management Policy”

2017.04.07

Announcement of Dividend of Surplus in the Fiscal Year Ended February 2017 (115th Fiscal Year)

2017.04.07

FY02/2017 Q4 Results Earnings Release Presentation

2017.03.29

Announcement regarding the Recording of Extraordinary Loss (Impairment Loss) of the U.S. Subsidiary, Noven Pharmaceuticals, Inc.

2017.03.29

Announcement regarding Discontinuation (Abolition) of Countermeasures on the Large-scale Purchase of Hisamitsu Shares, etc. (Takeover Defense Measures)

2017.01.13

FY02/2017 Q3 Results Earnings Release Presentation